Emotional distress and clinical response to neoadjuvant chemoimmunotherapy in resectable non-small-cell lung cancer: a protocol for the prospective observational NeoFUSE-Lung cohort study Authors: Yuanpu Wei, Hancheng Yin, Deliang Hou, Hao Chen, Guobing Xu, Bin Zheng, Chun Chen, Zhang Yang Published: 2026 ABSTRACT AbstractBackgroundNeoadjuvant chemoimmunotherapy (NACI) has improved pathological and survival outcomes in patients with resectable non-small-cell lung cancer (NSCLC), yet marked heterogeneity in treatment response persists. Emotional distress (ED) may modulate antitumor immunity through neuroendocrine and immune-related mechanisms, but its association with response to NACI in patients with resectable NSCLC remains insufficiently explored. This study aims to prospectively evaluate the relationship between ED and clinical outcomes in patients with resectable NSCLC receiving NACI, with exploratory analyses of stress-related biomarkers and gut microbiome profiles.MethodsThis single-center, prospective observational cohort study will enroll patients with treatment-naïve, resectable stage II–IIIB NSCLC scheduled to receive first-line NACI at Fujian Medical University Union Hospital. All participants will receive NACI as part of routine clinical care, and no experimental intervention will be assigned. ED will be assessed using the Hospital Anxiety and Depression Scale (HADS) at baseline and after two cycles of NACI, and participants will be classified according to baseline ED status and longitudinal ED trajectories. Clinical, psychological, quality-of-life, biochemical, and fecal microbiome data will be collected at prespecified time points. The primary outcomes are overall survival (OS) and progression-free survival (PFS). Secondary outcomes include objective response rate (ORR), pathological complete response (pCR), major pathological response (MPR), and quality of life (QoL). Associations between ED and clinical outcomes will be analyzed using appropriate regression and survival models, with exploratory analyses of stress-related biomarkers and gut microbiome profiles.DiscussionThis trial aims to provide prospective data on the association between ED and response to NACI in patients with resectable NSCLC, while exploring potential neuroimmune-microbiome pathways underlying this association.Trial RegistrationChinese Clinical Trial Registry (ChiCTR) identifier: ChiCTR2600119872.Keywords: Resectable non-small-cell lung cancer (resectable NSCLC), emotional distress (ED), neoadjuvant chemoimmunotherapy (NACI), gut microbiome Introduction Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of all cases (1). The incorporation of immune checkpoint inhibitors (ICIs) into chemotherapy regimens has revolutionized the management of NSCLC, establishing neoadjuvant chemoimmunotherapy (NACI) as a new therapeutic paradigm for resectable disease. Phase II and III trials have demonstrated that NACI significantly improves pathological response rates and long-term survival compared with chemotherapy alone. However, substantial interpatient variability persists, and a subset of patients fails to achieve durable benefit due to primary or acquired resistance (2,3). While tumor-intrinsic factors such as programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and soluble immune checkpoint molecules show predictive value, they only partly account for the heterogeneity of clinical outcomes (4,5). Increasing evidence suggests that host-related biological and psychosocial factors influence immune function and may modulate treatment efficacy (6). Among these, emotional distress (ED)—characterized by anxiety and depression—activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic-adrenal-medullary system, leading to the release of glucocorticoids and catecholamines (7,8). These stress mediators suppress T-cell and natural killer cell activity, promote T-cell exhaustion, and enhance the accumulation of myeloid-derived suppressor cells, collectively generating an immunosuppressive tumor microenvironment that may attenuate the effects of chemoimmunotherapy (9-13). Recent studies have linked higher levels of pretreatment ED to poorer responses and survival outcomes in patients treated with ICIs (14-16). Furthermore, emerging research has revealed a close interplay between psychological stress, neuroimmune signaling, and gut microbiota composition (17,18). Given that the gut microbiome also influences responsiveness to ICIs, perturbations induced by ED may indirectly affect chemoimmunotherapy efficacy. ED is highly prevalent among patients with cancer and is independently associated with worse prognosis (19-22). ED can be identified through standardized questionnaires, particularly in the context of cancer diagnosis and treatment-related challenges (20). In NSCLC, screening studies using validated instruments, including the Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) have shown a substantial burden of ED across disease stages (23-25). In metastatic NSCLC, patient-reported distress has been frequently observed during treatment with immuno-oncology agents (26). Recent studies using trajectory-based modeling have characterized distinct patterns of ED during NSCLC treatment, supporting the need for longitudinal assessment and targeted psychosocial intervention (27,28). Beyond its high prevalence and dynamic course, meta-analyses have further supported ED as a prognostic factor for poorer survival in advanced NSCLC (29,30). In the neoadjuvant setting, our previous HADS-based retrospective analysis showed that ED independently predicted long-term survival beyond pathological staging (31). Additionally, perioperative ED has been associated with poorer postoperative quality of life (QoL), increased postoperative pain, higher complication rates, and worse long-term physical function and sleep quality after lung cancer surgery (32-34). Although these findings have led to increasing interest in multimodal prehabilitation and psychological interventions (35,36), prospective evidence and biological mechanistic insights remain limited in the thoracic-surgical cohort of patients with resectable NSCLC receiving NACI. Based on these findings, we initiated the NeoFUSE-Lung Trial, a prospective observational study investigating the relationship between ED and clinical outcomes in patients with resectable NSCLC treated with first-line NACI. We hypothesize that higher baseline or sustained ED will be associated with diminished pathological and survival benefits. Additionally, through integrated analyses of psychological assessments, QoL scores, serum stress hormone levels, and fecal microbiota profiles, this study aims to elucidate the neuroimmune mechanisms linking ED with treatment response to NACI. We present this article in accordance with the SPIRIT reporting checklist (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0586/rc). Methods Study design This study is a single-center, prospective observational cohort study conducted at Fujian Medical University Union Hospital. The NeoFUSE-Lung cohort is designed to evaluate whether ED, as the central exposure of interest, is associated with clinical response in patients with resectable NSCLC receiving first-line NACI in routine clinical practice. Patient recruitment will occur between March 2026 and August 2027, with each participant followed for a minimum of 5 years after enrollment. All eligible patients will receive NACI as part of routine clinical care according to institutional protocols and national guidelines, with relevant assessments and biospecimen collection. No experimental intervention will be introduced. As this is an observational study, no formal sample size calculation was performed. Data will be collected at prespecified time points, including baseline (prior to initiation of NACI), after completion of two NACI cycles, preoperatively, and during postoperative follow-up. Clinical, psychological, biochemical, and microbiological parameters will be prospectively recorded in an electronic case-report form system. The primary endpoints are overall survival (OS) and progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), pathological complete response (pCR), major pathological response (MPR), and QoL. The study also explores mechanistic correlates linking ED with stress and gut microbiome characteristics. The Schema of this study is shown in Figure 1. The schema of NeoFUSE-Lung Trial. AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HADS, Hospital Anxiety and Depression Scale; NACI, neoadjuvant chemoimmunotherapy; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QoL, quality of life; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase. Patient and public involvement Patients and members of the public were not involved in the design of the study, the choice of outcome measures, recruitment strategies, or conduct of the research. Participants’ contributions were limited to providing study data (questionnaire responses, clinical information, biospecimens) at prespecified time points during routine care. No patients or public representatives were involved in the interpretation of results or preparation of this protocol or the planned manuscripts. Participants and inclusion/exclusion criteria Inclusion criteria Age ≥18 years. Age ≥18 years. Histologically or cytologically confirmed, treatment-naïve NSCLC. Histologically or cytologically confirmed, treatment-naïve NSCLC. Stage II–IIIB [according to 8th edition of the American Joint Committee on Cancer (AJCC)] and deemed resectable by a board-certified thoracic surgeon [multidisciplinary team (MDT) review per institutional practice]. Stage II–IIIB [according to 8th edition of the American Joint Committee on Cancer (AJCC)] and deemed resectable by a board-certified thoracic surgeon [multidisciplinary team (MDT) review per institutional practice]. Eastern Cooperative Oncology Group (ECOG) performance status 0–1 (Appendix 1). Eastern Cooperative Oncology Group (ECOG) performance status 0–1 (Appendix 1). At least one measurable lesion per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 documented on baseline imaging. At least one measurable lesion per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 documented on baseline imaging. Planned first-line NACI consisting of a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor in combination with chemotherapy. Planned first-line NACI consisting of a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor in combination with chemotherapy. Written informed consent obtained prior to the trial. Written informed consent obtained prior to the trial. Adequate organ and marrow function per institutional thresholds to safely receive NACI. Adequate organ and marrow function per institutional thresholds to safely receive NACI. Exclusion criteria Actionable oncogenic drivers: EGFR exon 19 deletion or exon 21 L858R, ALK fusion, or ROS1 fusion positivity. Actionable oncogenic drivers: EGFR exon 19 deletion or exon 21 L858R, ALK fusion, or ROS1 fusion positivity. Concurrent malignancy or prior malignancy within the past 10 years. Concurrent malignancy or prior malignancy within the past 10 years. Participation in other clinical trials that could interfere with study assessments or outcomes. Participation in other clinical trials that could interfere with study assessments or outcomes. Current acute or chronic psychiatric disorder or cognitive impairment (Appendix 1). Current acute or chronic psychiatric disorder or cognitive impairment (Appendix 1). Current antidepressant or anxiolytic therapy or psychotherapy within the past 6 months. Current antidepressant or anxiolytic therapy or psychotherapy within the past 6 months. Systemic corticosteroid therapy (continuous use) within 1 month prior to baseline assessment (physiologic replacement doses permitted). Systemic corticosteroid therapy (continuous use) within 1 month prior to baseline assessment (physiologic replacement doses permitted). Active infection, active or refractory autoimmune disease, or uncontrolled systemic illness that could confound outcomes or pose excess risk. Active infection, active or refractory autoimmune disease, or uncontrolled systemic illness that could confound outcomes or pose excess risk. Inability, because of illiteracy, poor reading comprehension, or communication difficulties, to complete questionnaire-based assessments with sufficient reliability, even with standardized assistance. Inability, because of illiteracy, poor reading comprehension, or communication difficulties, to complete questionnaire-based assessments with sufficient reliability, even with standardized assistance. Inability to use mobile-based study applications required for scheduled questionnaires or electronic Patient-Reported Outcomes (e-PRO) data capture. Inability to use mobile-based study applications required for scheduled questionnaires or electronic Patient-Reported Outcomes (e-PRO) data capture. Screening and enrollment procedures Eligibility will be confirmed using clinical records, pathology reports, and staging work-up [thin-slice chest computed tomography (TSCT), whole-body positron emission tomography/computed tomography (PET/CT), brain magnetic resonance imaging (MRI), bone scan, and abdominal computed tomography (CT) as indicated]. Suspicious mediastinal or supraclavicular nodes will undergo pathologic confirmation [e.g., endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), invasive mediastinal staging, or supraclavicular node biopsy]. Molecular testing for exclusionary drivers will be performed on diagnostic tissue obtained by bronchoscopy or percutaneous biopsy. Consented, eligible participants will initiate NACI per treating physician; at least two cycles are planned prior to surgery, with resection targeted within 6 weeks after the final neoadjuvant cycle. Treatment procedures Participants will receive NACI as part of routine clinical care according to institutional protocols and national guidelines. Acceptable ICIs include PD-1/PD-L1 inhibitors recommended by the Chinese Society of Clinical Oncology (CSCO) guidelines and approved by the China National Medical Products Administration (NMPA) for the first-line treatment of NSCLC (e.g., pembrolizumab, nivolumab, atezolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab). For nonsquamous NSCLC, platinum plus pemetrexed will be administered; for squamous NSCLC, platinum combined with paclitaxel, nab-paclitaxel, or gemcitabine will be used. The neoadjuvant phase will consist of 3 to 6 cycles of NACI, administered every 3 weeks, with a minimum of two cycles required prior to surgery. The exact number of cycles may be adjusted based on tumor response, patient tolerance, and MDT evaluation. Definitive surgical resection, following institutional standards for anatomical lobectomy and systematic lymph node dissection, is planned within 6 weeks after completion of the final neoadjuvant cycle, provided that there is no evidence of disease progression or medical contraindication to surgery. Perioperative management and scheduling will adhere to institutional protocols. Radiographic evaluations (e.g., TSCT with or without PET/CT as clinically indicated) will inform fitness for surgery after neoadjuvant therapy and will be interpreted per RECIST v1.1 by qualified radiologists. Treatment modifications, delays, or discontinuations (e.g., due to toxicity or intercurrent illness) will be recorded in the electronic data capture platform and managed per drug labels and institutional guidelines. Adjuvant therapy, when indicated based on final pathology and contemporary guidelines, will be administered at the investigator’s discretion and documented. For patients achieving R0 resection, adjuvant immunotherapy will be continued with the same ICIs used preoperatively, for a total duration of up to one year of immunotherapy, unless unacceptable toxicity or disease recurrence occurs. For high-risk patients (e.g., those with residual viable tumor or without MPR), 1–2 cycles of histology-appropriate platinum-based chemotherapy may be administered prior to maintenance immunotherapy, following MDT evaluation. For patients with non-R0 resection, management will follow the principles for unresectable or residual disease, incorporating local radiotherapy and systemic therapy as appropriate. No study-related intervention will be administered. Adverse events associated with NACI will be systematically collected from medical records and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Measurement of ED ED will be assessed using the HADS, a validated self-report instrument for detecting anxiety and depressive symptoms in medical populations. The HADS comprises 14 items, divided into two subscales: anxiety (HADS-A) and depression (HADS-D). Each subscale contains seven items rated on a 4-point Likert scale [0–3], reflecting symptom frequency from “not at all” to “most of the time”. The subscale scores range from 0 to 21, with higher scores indicating greater symptom burden (37). ED assessments will be performed at two prespecified time points (Appendix 1): (I) baseline—prior to initiation of NACI, and (II) after completion of two NACI cycles and before surgical evaluation. Based on validated cut-offs (38-41), patients scoring ≥8 on either the HADS-A or HADS-D subscale will be classified as having ED (ED group), while those with scores <8 on both subscales will be assigned to the non-ED (normal) group in this study. To capture longitudinal patterns, participants will also be considered for classification into four ED trajectory subgroups: Sustained ED: HADS-A/HADS-D score ≥8 at both time points; Sustained ED: HADS-A/HADS-D score ≥8 at both time points; Developed ED: HADS-A/HADS-D score ≥8 only after NACI treatment; Developed ED: HADS-A/HADS-D score ≥8 only after NACI treatment; Remitted ED: HADS-A/HADS-D score ≥8 only at baseline; Remitted ED: HADS-A/HADS-D score ≥8 only at baseline; Unaffected ED: HADS-A/HADS-D score <8 at both assessments. Unaffected ED: HADS-A/HADS-D score <8 at both assessments. In addition to cutoff-defined ED groups, changes in HADS-A, HADS-D, and total HADS scores will be analyzed as continuous variables. ΔHADS scores will be calculated as the score at the second assessment minus the baseline score, with positive values indicating worsening ED and negative values indicating improvement. The HADS has been widely validated in oncology populations, demonstrating good reliability and discriminative accuracy while minimizing confounding from somatic symptoms of cancer or its treatment. In this study, the HADS serves as a general screening tool to capture the overall symptom burden of anxiety and depression arising from cancer diagnosis and treatment-related challenges, rather than as a diagnostic basis for clinical psychiatric disorders such as major depressive disorder (MDD) or GAD. To complement this general assessment, the PHQ-9 and the GAD-7 may be considered as complementary measures for future sensitivity analyses and cross-validation of specific symptom domains. Standardized administration and scoring procedures will be followed to ensure consistency across all participants. Measurement of QoL Health-related QoL will be evaluated as a patient-reported clinical endpoint and examined in relation to ED status in exploratory analyses. QoL will be assessed using the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30; Chinese version), a validated instrument widely used in oncology (42,43). This self-report questionnaire for cancer patients includes a global health status, five functional subscales (physical, role, emotional, cognitive, and social), three symptom subscales (fatigue, nausea/vomiting, and pain), and six individual symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The two global health status items are scored on a 7-point Likert scale (from “very poor” to “excellent”), whereas all other items are based on a 4-point Likert scale (from “not at all” to “very much”), with overall scores ranging from 0 to 100. Higher scores on the global health status and functional scales denote a better QoL, whereas higher scores on the symptom scales are indicative of impaired QoL. QoL assessments are scheduled at two time points: (I) baseline, prior to initiation of NACI, and (II) after two NACI cycles and before surgical evaluation. Follow-up Radiologic response assessments (TSCT or PET/CT) will be performed after every two cycles of neoadjuvant therapy and at the end of the neoadjuvant course, interpreted according to RECIST v1.1 by qualified radiologists. In addition, participants will undergo clinical and laboratory evaluations at each treatment cycle to monitor safety, treatment tolerance, and interim response. Following surgery, participants will be followed every 3 months during the first 2 years, every 6 months during years 3–5, and annually thereafter for survival status and disease assessment, in accordance with institutional practice. Sample collection Previous studies have suggested that ED may influence antitumor immunity through neuroendocrine stress pathways, including activation of the HPA axis and the sympathetic-adrenal-medullary system, which are reflected by stress mediators such as cortisol, noradrenaline, and adrenaline (7,8). Emerging evidence also highlights the role of the microbiota-gut-brain axis in neuroimmune regulation (44), suggesting that gut microbiome alterations across different ED statuses may be associated with differential outcomes after NACI. Recent clinical evidence in NSCLC further indicates that ED is associated with altered serum cortisol levels, while gut microbiome changes during ICI-based therapy may be related to patient prognosis (16,18). Based on this evidence, we will collect blood and fecal samples to explore a prespecified neuroendocrine-microbiome-immune framework. Specifically, we hypothesize that patients with ED, particularly those in sustained or developed ED groups, may exhibit greater activation of the HPA axis and sympathetic-adrenal-medullary system, as reflected by higher circulating cortisol and adrenocorticotropic hormone (ACTH) levels; gut microbiome dysbiosis, including reduced microbial diversity, altered community structure, and changes in immune-modulatory taxa; and that these biological features may mediate or moderate the association between ED and clinical response to NACI. To minimize confounding factors, participants will be instructed to abstain from alcohol, caffeine, and tobacco for at least 12 hours prior to sample collection and to rest in a supine position for 15 minutes before blood draw. Venous blood samples will be collected at 8:00 AM from all enrolled participants before administration of NACI to control for diurnal variation. Serum levels of cortisol and ACTH will be measured as part of the routine pre-treatment evaluation using Siemens ADVIA Centaur XP and IMMULITE 2000XPi immunoassay systems, respectively. Additional aliquots of serum and plasma will be stored at –80 °C for subsequent biomarker analyses. Fecal samples will be collected at three time points (Appendix 1): Baseline—from 2 days before to 1 day after initiation of NACI; Baseline—from 2 days before to 1 day after initiation of NACI; Preoperatively—following completion of neoadjuvant therapy but prior to surgery; Preoperatively—following completion of neoadjuvant therapy but prior to surgery; Postoperatively—3 months after surgical resection. Postoperatively—3 months after surgical resection. Fecal specimens will be collected using commercially available stool collection tubes, transported to the central laboratory on dry ice, and stored at −80 °C until DNA extraction. Microbiome analysis will be performed using 16S ribosomal RNA (rRNA) gene sequencing (V3–V4 region) and processed with the QIIME 2 bioinformatics pipeline to evaluate microbial diversity and taxonomic composition. All biospecimens will be labeled with anonymized study identifiers and handled according to institutional biosafety and ethical guidelines. Outcome measures Primary outcomes OS: time from initiation of NACI to death from any cause. OS: time from initiation of NACI to death from any cause. PFS: time from initiation of NACI to the first documented disease progression or death from any cause, whichever occurs first. Disease progression will be determined radiographically according to RECIST v1.1 and/or pathologically, as appropriate. PFS: time from initiation of NACI to the first documented disease progression or death from any cause, whichever occurs first. Disease progression will be determined radiographically according to RECIST v1.1 and/or pathologically, as appropriate. Secondary outcomes ORR: proportion of participants achieving complete response (CR)—disappearance of all target lesions with all pathological lymph nodes <10 mm in short axis—or partial response (PR)—≥30% decrease in the sum of diameters of target lesions—per RECIST v1.1 on preoperative imaging. ORR: proportion of participants achieving complete response (CR)—disappearance of all target lesions with all pathological lymph nodes <10 mm in short axis—or partial response (PR)—≥30% decrease in the sum of diameters of target lesions—per RECIST v1.1 on preoperative imaging. pCR: no residual viable tumor in the resected primary tumor and all sampled regional lymph nodes. pCR: no residual viable tumor in the resected primary tumor and all sampled regional lymph nodes. MPR: ≤10% residual viable tumor in the resected primary tumor specimen, assessed by dedicated thoracic pathologists using standardized protocols. MPR: ≤10% residual viable tumor in the resected primary tumor specimen, assessed by dedicated thoracic pathologists using standardized protocols. QoL: scores from the EORTC QLQ-C30 (Chinese version), analyzed per scoring manual (0–100 transformation), with higher global/functional scores indicating better QoL and higher symptom scores indicating greater symptom burden. QoL: scores from the EORTC QLQ-C30 (Chinese version), analyzed per scoring manual (0–100 transformation), with higher global/functional scores indicating better QoL and higher symptom scores indicating greater symptom burden. Assessment schedule Radiologic response (for ORR and progression events) will be evaluated after every two NACI cycles and at the end of the neoadjuvant course, per RECIST v1.1. Radiologic response (for ORR and progression events) will be evaluated after every two NACI cycles and at the end of the neoadjuvant course, per RECIST v1.1. Pathologic endpoints (MPR, pCR) will be assessed on definitive surgical specimens following completion of NACI. Pathologic endpoints (MPR, pCR) will be assessed on definitive surgical specimens following completion of NACI. QoL will be measured at baseline (pre-NACI) and after two NACI cycles prior to surgical evaluation. QoL will be measured at baseline (pre-NACI) and after two NACI cycles prior to surgical evaluation. Survival status will be obtained at routine follow-up visits approximately every 3 months and via medical records. Survival status will be obtained at routine follow-up visits approximately every 3 months and via medical records. Exploratory analyses Associations between ED status/trajectories and biological correlates (e.g., serum cortisol/ACTH, gut microbiome diversity and composition) with clinical endpoints (OS, PFS, ORR, MPR, pCR, QoL) will be explored using prespecified statistical models. Statistical analysis All analyses will be conducted on the prospectively enrolled cohort, with time-to-event outcomes measured from initiation of NACI. Participants will be stratified by ED status/trajectory for all primary and secondary analyses. Continuous variables will be presented as mean [standard deviation (SD)] or median [interquartile range (IQR)], depending on their distribution; categorical variables will be expressed as number (percentage). Between-group comparisons will use independent t-tests or Mann-Whitney U tests for continuous data and χ2 tests or Fisher’s exact tests for categorical data, based on distributional assumptions. Survival analyses OS and PFS will be estimated using Kaplan-Meier methods and compared with the log-rank test. Multivariable Cox proportional hazards models will estimate the association between ED and survival outcomes, reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Variables with P<0.10 in univariable survival analyses will be considered for inclusion in multivariable models. In addition, variables identified a priori based on clinical knowledge and previous literature regarding their prognostic relevance in NSCLC, including age, sex, ECOG performance status, clinical stage, histology, smoking status, and PD-L1 expression, will also be considered for inclusion in multivariable models. PD-L1 expression will be included because different PD-L1 expression levels may be associated with differential response and survival outcomes in patients receiving ICI-based therapy. Post hoc subgroup analyses will be performed according to prespecified variables, including age, sex, ECOG performance status, clinical stage, histology, smoking status, and PD-L1 expression status, to describe the association between ED and survival outcomes across different clinical subgroups. Statistical significance and software Two-sided P<0.05 will be considered statistically significant unless otherwise specified. Analyses will be performed using SPSS (IBM, Armonk, NY) and R (R Foundation, Vienna, Austria). Missing data will be addressed using appropriate methods, including multiple imputation and sensitivity analyses, according to the extent and pattern of missingness. Gut microbiome analysis Fecal microbial profiling will be performed using 16S rRNA gene amplicon sequencing targeting the V3–V4 hypervariable regions. Raw paired-end sequencing reads will first undergo demultiplexing according to sample-specific barcodes. Primer and adapter sequences will be removed using Cutadapt. Subsequent quality control, denoising, paired-end read merging, and chimera removal will be conducted using the DADA2 algorithm implemented in the QIIME 2 pipeline (45,46). This approach will generate amplicon sequence variants (ASVs), which provide higher-resolution and more reproducible taxonomic features than traditional operational taxonomic units. Taxonomic classification of ASVs will be performed using a Naïve Bayes classifier trained on the SILVA 138 reference database (47), trimmed to the amplified V3–V4 region. ASVs assigned to mitochondria, chloroplasts, or unclassified non-bacterial sequences will be removed prior to downstream analyses. A phylogenetic tree will be constructed using MAFFT for multiple sequence alignment and FastTree for approximate maximum-likelihood tree inference, enabling phylogeny-based diversity analyses (48,49). Microbial diversity will be assessed at both within-sample and between-sample levels. Alpha diversity will be evaluated using the Shannon index, observed ASVs, Chao1 richness estimator, and Faith’s phylogenetic diversity. Between-group differences in alpha diversity will be examined using the Wilcoxon rank-sum test or Kruskal-Wallis test, as appropriate. Beta diversity will be assessed using Bray-Curtis dissimilarity, Jaccard distance, and weighted and unweighted UniFrac distances. Principal coordinate analysis (PCoA) will be used for visualization. Differences in microbial community composition across ED status, treatment response groups, and longitudinal sampling time points will be tested using permutational multivariate analysis of variance (PERMANOVA) via vegan R package (50). To identify microbial taxa associated with ED and NACI response, differential abundance analyses will be performed using complementary methods. ANCOM-BC2 will be used as the primary compositional data-aware method to estimate differentially abundant taxa while correcting for sampling fraction bias. MaAsLin2 will be applied for multivariable association analyses, allowing adjustment for clinically relevant covariates, including age, sex, smoking status, histology, clinical stage, body mass index, antibiotic exposure, proton-pump inhibitor use, PD-L1 expression, treatment regimen, and baseline dietary or lifestyle factors where available. LEfSe analysis will be used as an exploratory approach to identify discriminative microbial features among predefined groups, with linear discriminant analysis scores used to rank taxa with the greatest discriminatory effect (51). Longitudinal microbiome changes from baseline to preoperative and postoperative time points will be analyzed using mixed-effects models, with patient identifier included as a random effect to account for repeated measurements. Changes in alpha diversity, beta diversity, and taxon-level abundance will be evaluated according to ED trajectories, including sustained ED, developed ED, remitted ED, and unaffected ED. Associations between microbial features and clinical endpoints, including ORR, MPR, pCR, PFS, and OS, will be explored using logistic regression, Cox proportional hazards models, or Spearman correlation analyses, depending on the outcome type. To explore potential neuroimmune-microbiome interactions, microbial diversity indices and selected taxa will be correlated with psychological scores, quality-of-life scores, and serum stress biomarkers, including cortisol and ACTH. Where appropriate, exploratory mediation analyses will be conducted to assess whether stress-related biological or microbial features partially mediate the association between ED and treatment response. Multiple testing will be controlled using the Benjamini-Hochberg false discovery rate method, with adjusted P values reported for differential abundance and correlation analyses. Microbiome-related analyses will be conducted primarily using QIIME 2 and the R statistical environment. Relevant R packages, including but not limited to phyloseq, vegan, microbiome, ANCOMBC, MaAsLin2, DESeq2, ggplot2, and mixOmics, will be used as appropriate. The analysis workflow, software versions, reference database versions, and key parameters will be documented to ensure reproducibility. Ethics and dissemination The study will be conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Ethics Committee of Fujian Medical University Union Hospital (No. 2026KY070). The current protocol is Version 1.2, dated 31 August 2025. Written informed consent will be obtained from all participants by trained investigators or authorized research staff prior to enrollment. The consent form will include provisions for the collection, storage, and use of participant data and biological specimens for the present study and related ancillary analyses, where applicable. Participant confidentiality will be protected through the use of anonymized study identifiers. Access to identifiable information will be restricted to authorized study personnel only. Study data will be stored on secure, access-controlled servers in accordance with institutional policies. Any important protocol modifications, including changes to eligibility criteria, outcomes, or statistical analyses, will be submitted to the ethics committee for approval and updated in the trial registry where applicable. The results of this study will be disseminated through peer-reviewed publications and presentations at national and international scientific conferences. Where appropriate, aggregated findings will also be communicated to participants and stakeholders in lay summaries. Trial status This trial has been registered with the Chinese Clinical Trial Registry (ChiCTR; www.chictr.org.cn) (ChiCTR2600119872). Registered on 04 March 2026. Discussion ED is prevalent among patients with cancer and has been associated with adverse outcomes, including higher cancer-specific and all-cause mortality, with a particularly salient signal in lung cancer (52). Given this burden, oncology societies advocate routine screening and management of anxiety and depressive symptoms across the cancer care continuum (53,54). Concurrently, integrating ICIs with platinum-based chemotherapy has reshaped the neoadjuvant treatment paradigm for resectable NSCLC, improving MPR, ORR, and longer-term outcomes relative to chemotherapy alone; however, marked inter-patient heterogeneity persists, and a subset derives limited benefit (55,56). These observations highlight the need to complement tumor-intrinsic biomarkers with host-related determinants of treatment efficacy (57). A growing body of mechanistic evidence supports a biologically plausible link between ED and diminished immunotherapy benefit. Activation of stress-response axes leads to glucocorticoid and catecholamine release, which can impair CD8+ T-cell and NK-cell function, promote T-cell exhaustion, and drive the accumulation of myeloid-derived suppressor cells—collectively fostering an immunosuppressive tumor microenvironment (9-13). Preclinical models further implicate β2-adrenergic signaling and glucocorticoid receptor pathways in resistance to PD-1-based therapy (58,59). In line with these mechanisms, clinical studies in melanoma and NSCLC have reported that higher pretreatment ED is associated with poorer ICI response and outcomes, supporting ED as a clinically relevant host factor (15,16). The NeoFUSE-Lung study is designed to address this gap by prospectively characterizing ED using the HADS and relating both baseline status and longitudinal trajectories to pathologic and survival endpoints in resectable NSCLC. HADS was selected for its feasibility in oncology settings and its emphasis on psychological rather than somatic symptoms (37). Given that prior comparative work suggests broadly similar screening performance versus PHQ-9/GAD-7 (38-41), we employed a subscale cutoff of ≥8 to optimally balance sensitivity and specificity within our observational design. Mounting evidence also points to a role for the gut microbiome in modulating responsiveness and toxicity to ICIs (18,60-66). Because psychological stress can perturb gut microbial composition (67), our exploratory fecal microbiome profiling may help clarify whether ED-associated dysbiosis contributes to heterogeneous NACI efficacy in NSCLC, thereby generating testable hypotheses about neuroimmune-microbial crosstalk. Several limitations merit consideration. First, the single-center design may constrain generalizability; however, our findings will complement multicenter observations linking ED and immunotherapy outcomes in advanced NSCLC (16). Second, we assess serum cortisol rather than unbound cortisol, which may more closely reflect biologically active glucocorticoid exposure (68). Third, reliance on a single primary distress instrument (HADS) without repeated confirmation using additional scales could introduce measurement bias; nonetheless, additional PHQ-9 and GAD-7 assessments could provide an avenue for cross-validation in sensitivity analyses (16,38-41). Future multicenter studies employing standardized, multimodal stress phenotyping and harmonized biospecimen workflows will be important to enhance external validity and mechanistic inference. In summary, NeoFUSE-Lung will prospectively evaluate the association between ED and clinical outcomes after NACI in resectable NSCLC, while exploring biological intermediates that may link psychological stress to variable treatment benefit. Should ED prove prognostic or predictive, these results would support integrating routine psychosocial screening into perioperative pathways and piloting scalable distress-reduction strategies alongside NACI to optimize outcomes. Supplementary The article’s supplementary files as Acknowledgments The authors would like to thank all patients and their families who will participate in this study, as well as the clinical and research staff involved in the study. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study will be conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Ethics Committee of Fujian Medical University Union Hospital (No. 2026KY070). Written informed consent will be obtained from all participants by trained investigators or authorized research staff prior to enrollment. Footnotes Reporting Checklist: The authors have completed the SPIRIT reporting checklist. Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0586/rc Funding: This work was supported by Talent Fund Project of Fujian Medical University Union Hospital (No. 2021XH029) and Joint Fund for the innovation of science and Technology, Fujian province (No. 2023Y9204). The funding source was not involved in the study design, data curation, data analysis or interpretation, writing of the manuscript or the decision to submit it for publication. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0586/coif). Z.Y. reports support from Talent Fund Project of Fujian Medical University Union Hospital and Joint Fund for the Innovation of Science and Technology, Fujian province. The other authors have no conflicts of interest to declare. References Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0586/prf Supplementary Materials The article’s supplementary files as